#2
|
|||
|
|||
AW: Neues Medikament Tivozanib
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Purpose Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC)........................... http://ascopubs.org/doi/10.1200/JCO.2012.47.4940 Tivozanib war jetzt also nicht wirklich so viel besser als Sorafenib. Leider. Geändert von gitti2002 (25.03.2017 um 20:20 Uhr) |
Lesezeichen |
Aktive Benutzer in diesem Thema: 1 (Registrierte Benutzer: 0, Gäste: 1) | |
|
|